Rhovac hires investment bank to generate interest in lead candidate

Biotech company Rhovac is on the lookout for a deal or a partnership regarding its lead candidate. International investment managing firm Stifel Nicolaus Europe has been appointed to help with the task.

Photo: Jens Dresling

Danish biotech company Rhovac, spearheaded by Anders Månsson, former executive of  Leo Pharma and Ferring Pharmaceuticals, has made it its goal to examine the opportunities of either striking a deal or entering a partnership pertaining to its lead candidate RV001, the company reports in a press relase on Monday.

RV001, which is a RhoC based cancer vaccine, was granted the Fast Track Designation by the US Food and Drug Administration (FDA) last year.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Further reading

Related articles

Trial banner

Latest news

See all jobs